Título:	Citotoxicidade e atividade antitumoral de Paclitaxel em lipossomas em modelo experimental de tumor de ovário metastático
Autor(es):	Faria, Raquel Santos
Orientador(es):	Azevedo, Ricardo Bentes de
Assunto:	Ovários - câncer Carcinomatose peritoneal Lipossomas Medicamentos
Data de publicação:	24-Abr-2026
Data de defesa:	2020
Referência:	FARIA, Raquel Santos. Citotoxicidade e atividade antitumoral de Paclitaxel em lipossomas em modelo experimental de tumor de ovário metastático. 2020. 96 f., il. Tese (Doutorado em Biologia Animal) — Universidade de Brasília, Brasília, 2020.
Abstract:	Ovarian cancer is considered a chemosensitive disease, so chemotherapy is very important when considering systemic treatment. However, recurrence occurs in about 80% of patients, thus requiring the development of more effective therapies. There are two main types of treatment for ovarian cancer: surgery and chemotherapy. The use of chemotherapy is based mainly on platinum and taxol compounds, and as a second line, non-platinum based drugs, such as liposomal doxorubicin, are used. Liposomes serve as nanocarriers for chemotherapy, maintaining the rate of the drug in the bloodstream and their targeted delivery. The aim of the project was to evaluate the in vitro effect of PTX carried by a liposomal nanosystem (LFCP PTX) on ovarian epithelial carcinoma cells (A2780), and in vivo antitumor activity and toxicity in an experimental study model of peritoneal ovarian carcinomatosis in mice. In in vitro tests, cell viability results against the A2780 tumor line showed a 50% decrease in inhibitory concentration when using LFCP PTX compared to free PTX. The percentage of growth of A2780 cell colonies when treated with liposomal PTX was statistically different than the treatment with free PTX. Cell death profiles of A2780 cells with liposomal treatments were indicative of apoptosis, with most cells in early apoptosis. A2780 cells treated with the LFCP PTX exhibited a inhibition in the migration profile by the Wound Healing and 3D (xCELLigence) methods. This inhibition was promoted by the decrease in the gene expression of ZEB1 and TGFB2. In in vivo testing, treatment with LFCP PTX strongly inhibited tumor cell development and proliferation in ovarian peritoneal carcinomatosis, indicating high antitumor activity when compared to PTX free form. Also, LFP PTX group had lower systemic toxicity much closer to healthy animals than the animals treated with free PTX. Our results showed that the use of nanocarrier PTX in the LFCP liposome leads to more effective control of tumor cell proliferation in vitro and in vivo, including inhibition of migration via the ZEB1 and TGFB2 pathways, as well as reducing the systemic toxicity of PTX.
Unidade Acadêmica:	Instituto de Ciências Biológicas (IB)
Programa de pós-graduação:	Programa de Pós-Graduação em Biologia Animal
Aparece nas coleções:	Teses, dissertações e produtos pós-doutorado

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.